share_log

和誉-B(02256):FGFR4抑制剂依帕戈替尼获美国FDA授予孤儿药认定

Goodwill B (02256): The FGFR4 inhibitor ipagotinib was certified as an orphan drug by the US FDA

Zhitong Finance ·  Apr 24 19:47

Heyu-B (02256) issued an announcement. The company's subsidiary, Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu...

Zhitong Finance App News, Heyu-B (02256) announced that Shanghai Heyu Biomedical Technology Co., Ltd. (Fuyu Pharmaceutical), a subsidiary of the company, announced that its self-developed high-selective small molecule FGFR4 inhibitor ipagotinib (ABSK011) has been certified as an orphan drug by the US Food and Drug Administration (FDA) to treat hepatocellular carcinoma (Hepatocellular carcinoma, HCC).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment